Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.
Gonzalez-Serna A, Corma-Gomez A, Tellez F, Corona-Mata D, Rios-Villegas MJ, Merino D, Galera C, Collado-Romacho AR, De Los Santos I, Cucurull J, Santos M, García-Martín S, Rivero A, Real LM, Macias J. Gonzalez-Serna A, et al. Among authors: rios villegas mj. J Antimicrob Chemother. 2023 Oct 3;78(10):2591-2596. doi: 10.1093/jac/dkad278. J Antimicrob Chemother. 2023. PMID: 37671831 Free PMC article.
Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N, Rivero-Juárez A, Téllez F, Merino D, Ríos-Villegas MJ, Villalobos M, Omar M, Rincón P, Rivero A, Pérez-Pérez M, Raffo M, López-Montesinos I, Palacios R, Gómez-Vidal MA, Macías J, Pineda JA; Members of the HEPAVIR-Cirrhosis Study Group. Merchante N, et al. J Antimicrob Chemother. 2018 Sep 1;73(9):2435-2443. doi: 10.1093/jac/dky234. J Antimicrob Chemother. 2018. PMID: 29982683 Free article.
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J. Pineda JA, et al. J Antimicrob Chemother. 2007 Dec;60(6):1347-54. doi: 10.1093/jac/dkm373. Epub 2007 Oct 14. J Antimicrob Chemother. 2007. PMID: 17938129
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI. Crespo M, et al. J Antimicrob Chemother. 2008 Oct;62(4):793-6. doi: 10.1093/jac/dkn262. Epub 2008 Jun 21. J Antimicrob Chemother. 2008. PMID: 18567911
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA. Mira JA, et al. J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13. J Antimicrob Chemother. 2008. PMID: 18854330 Clinical Trial.
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Clin Infect Dis. 2013 Jun;56(11):1646-53. doi: 10.1093/cid/cit103. Epub 2013 Feb 19. Clin Infect Dis. 2013. PMID: 23429381
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.
Mira JA, Neukam K, López-Cortés LF, Rivero-Juárez A, Téllez F, Girón-González JA, de los Santos-Gil I, Ojeda-Burgos G, Merino D, Ríos-Villegas MJ, Collado A, Torres-Cornejo A, Macías J, Rivero A, Pérez-Pérez M, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI); Red de Investigación en SIDA (RIS-HEP07). Mira JA, et al. Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1879-84. doi: 10.1007/s10096-015-2426-6. Epub 2015 Jun 27. Eur J Clin Microbiol Infect Dis. 2015. PMID: 26115631
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.
Merchante N, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Merino D, Márquez-Solero M, Omar M, Recio E, Pérez-Pérez M, Camacho Á, Macías-Dorado S, Macías J, Lorenzo-Moncada S, Rivero A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Merchante N, et al. BMC Infect Dis. 2015 Dec 7;15:557. doi: 10.1186/s12879-015-1291-3. BMC Infect Dis. 2015. PMID: 26643257 Free PMC article.
45 results